Your browser doesn't support javascript.
loading
Design and synthesis of the first potent, selective, and cell penetrating adenosine 5'-monophosphate deaminase inhibitors.
Bookser, B C; Kasibhatla, S R; Appleman, J R; Erion, M D.
Affiliation
  • Bookser BC; Metabasis Therapeutics Inc., San Diego, California 92121, USA.
Adv Exp Med Biol ; 431: 853-7, 1998.
Article in En | MEDLINE | ID: mdl-9598184
ABSTRACT
A major milestone in purine metabolism research has been achieved with the discovery of these potent and selective AMPDA inhibitors. These inhibitors of AMPDA are based on carboxypentyl substitution on N-3 of the coformycin aglycon. They are simpler than coformycin ribose 5'-monophosphate, more stable, selective against other AMP binding enzymes as well as ADA and have good cell penetration and good oral bioavailability. These compounds and their more potent analogs are the first compounds with suitable characteristics to allow a definitive analysis of the role of AMPDA in cellular metabolism and AMPDA as a therapeutic target.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Coformycin / Enzyme Inhibitors / AMP Deaminase Type of study: Prognostic_studies Limits: Humans Language: En Journal: Adv Exp Med Biol Year: 1998 Document type: Article Affiliation country: United States
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Coformycin / Enzyme Inhibitors / AMP Deaminase Type of study: Prognostic_studies Limits: Humans Language: En Journal: Adv Exp Med Biol Year: 1998 Document type: Article Affiliation country: United States